GZMB, which can inhibit aberrant IL‐17 production in CD4+ T cells, thereby impeding angiogenesis and subsequent tumor development, was upregulated in CD4+ Th17 cells in HB group. This evidence concerns the gene CD4 and hemoglobin measurement.